Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

the NDA; NeurogesX' plans, and expected timing, with regard to seeking partnerships for its product candidates; the sufficiency of cash resources to fund the NeurogesX' operations through at least December 31, 2009; the ability to secure funding through commercial partnerships; expectations regarding expenses and cash burn rate; expectations with respect to seeking funding; the potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, positive results in clinical trials, or the recommendation of the CHMP for MAA approval, may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; unexpected expenses; inability to enter into or obtain adequate funding under commercial or other strategic partnerships; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


                                     NEUROGESX, INC.
                             
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... julio de 2014 ADB International Group ... anunciado hoy una asociación con Austen BioInnovation Institute ... el Instituto), para el propósito de llevar el ... de señal bioeléctrica (el E-QURE BST Device), al ... tiene una importante experiencia en cicatrización de heridas, ...
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
(Date:7/23/2014)... July 23, 2014 Shire ... the global specialty biopharmaceutical company, and ArmaGen, a ... worldwide licensing and collaboration agreement for AGT-182, an ... treatment of both the central nervous system (CNS) ... (MPS II). This collaboration strengthens Shire,s rare disease ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... , WASHINGTON, Sept. 15 BIO Ventures ... was elected chairman of the global health non-profit,s Board of Directors. ... its inception in 2004. , , ... with Melinda Moree and our board. Up to now, biotech ...
... , BASKING RIDGE, N.J., Sept. 15 Regado ... aptamers with active control agents, announced today that Chris ... America Conference 2009 in San Francisco, CA at 3:15 on ... include an overview of the Company,s pipeline with emphasis on ...
... , , , , ... 15 Treatment of hospital-related infections in the U.S. costs up to ... to medical devices implanted in patients. Until now, efforts to control drug-resistant ... New hydrogel mats developed by collaborators Pat Mather and Dacheng Ren ...
Cached Biology Technology:BVGH Announces New Board Chair 2Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009 2New Antimicrobial Webs Sterilize Medical Implants for 14 Days 2
(Date:7/23/2014)... called SUP05 will play an increasingly important role in ... oxygen minimum zones expand, according to research published this ... of Sciences . , University of British Columbia researchers ... Saanich Inlet, to chart how microbial community metabolism changes ... a very detailed picture of how SUP05 a ...
(Date:7/23/2014)... and forming knots. Scientists study these knots to understand ... useful for gene sequencing techniques). Cristian Micheletti, professor at ... and his team have been carrying out research in ... their latest paper, just published in the journal ... first author and PhD student at SISSA, and colleagues ...
(Date:7/23/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
Breaking Biology News(10 mins):Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2Nano-sized chip "sniffs out" explosives far better than trained dogs 2
... 2008 -- With reducing carbon emissions on the national agenda, ... and policy issues on how carbon sinks or carbon sequestration ... Carbon sequestration is the process through which carbon dioxide (CO ... and crops through photosynthesis, and stored as carbon in biomass ...
... tomography to Google searches, higher mathematics and computation are ... The University of Pennsylvania,s new graduate program in ... symposium to spotlight the frontiers of research and provide ... Talks will be given by international leaders in subjects ...
... restoration projects to protect storm buffeted infrastructure along the ... that provides "false hope" and prevents endangered communities from ... Western Carolina University (WCU). As hurricanes have ... has been filled with the words of politicians, policy ...
Cached Biology News:Carbon sinks: Issues, markets, policy 2Wetlands restoration not a panacea for Louisiana coast 2Wetlands restoration not a panacea for Louisiana coast 3
ZBP-89 (S-15)...
... forming), Acetate thiokinase Packaging: Package ... Physical form: Lyophilized powder containing stabilizers as ... Preparation Unit Definition: One unit will ... from acetate, ATP and coenzyme A per ...
... Display Vector is specifically designed to target ... of Saccharomyces cerevisiae. Displayed proteins can be ... known or putative ligands. pYD1 uses the ... two domains Aga1 and Aga2 to display ...
... S is a member of a class of ... the DNA sequence. Mut S plays an integral ... ,replication, in transcription-coupled nucleotide excision repair and in ... Mut S binds to DNA specifically at base ...
Biology Products: